Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Essential Biomarker Testing in GI Cancers

Listen to John L. Marshall, MD, discuss contemporary biomarker testing considerations in gastrointestinal tumors, including colon, gastric, biliary, and pancreas cancers.
John L. Marshall, MD
Released: August 18, 2021

In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including:

  • Current testing approaches, including IHC and PD-L1 assays and next-generation sequencing
  • Tumor agnostic testing: MSI, TMB, and NTRK fusion testing
  • Colon cancer: RAS, BRAF, and HER2
  • Gastric cancer: PD-L1, HER2, and more
  • Pancreatic cancer: BRCA
  • Biliary cancers: FGFR and IDH1
  • Liquid biopsies
  • When to test

Information on this Educational Activity

Faculty

John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees from Bayer, Caris, Indivumed, Daiichi Sankyo, and Taiho; salary from Indivumed; and fees for non-CME services from Bayer, Daiichi Sankyo, Merck, Pfizer, and Taiho.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Merck Sharp & Dohme Corp.

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on targeted and immunotherapies for HCC and BTCs

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: November 18, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the use of targeted therapies for advanced biliary tract cancer

Mark Yarchoan, MD Released: November 12, 2021

In slides from Clinical Care Options (CCO), experts discuss emerging data surrounding use of immune checkpoint inhibitors for early HCC

Amit G. Singal, MD, MS Released: November 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue